希玛眼科(03309.HK)斥3.85亿人币收购深圳爱康健55%股权 拓「眼+牙」连锁医疗服务
希玛眼科(03309.HK)公布,于9月3日与卖方谢昔耀、深圳同州及深圳睿霖订立协议,将出资价5,000万元人民币(下同),通过增资向深圳爱康健将发行的注册资本注资,占扩大后注册资本7.1%;并以3.35亿元向卖方收购深圳爱康健共47.9%注册资本,总投资金额共3.85亿元,将以内部资源拨付。
完成后,希玛外资企业将持有深圳爱康健55%股权,成为其控股股东,而谢昔耀、深圳同州及深圳睿霖则分别持股31.92%、1.65%及4.91%。
集团表示,深圳爱康健在深圳经营知名牙科连锁品牌,旗下平台广为人知,服务大量香港跨境病人,未来将探讨与深圳爱康健开拓眼科医院网络,提供一站式「眼+牙」连锁医疗服务,并将牙科服务新增至大湾区现有眼科医院及诊所网络。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.